Tagrisso's cost can vary significantly depending on factors such as insurance coverage, geographic location, and whether a patient is participating in a patient assistance program.
How much does Tagrisso cost without insurance?
Without insurance, a one-month supply of Tagrisso can cost approximately $10,000 to $12,000. This price can fluctuate, and individual pharmacies may have different pricing.
What are patient assistance programs for Tagrisso?
Pharmaceutical companies often offer patient assistance programs for high-cost medications like Tagrisso. These programs can help eligible patients with financial difficulties afford their treatment. For Tagrisso, AstraZeneca, the manufacturer, offers programs that may reduce out-of-pocket expenses for eligible patients. Information on these programs is typically available through the drug manufacturer's website or by discussing options with a healthcare provider.
How does insurance affect Tagrisso cost?
Insurance coverage plays a crucial role in determining a patient's out-of-pocket cost for Tagrisso. With insurance, copays can range from a few dollars to several hundred dollars per month, depending on the specific insurance plan, deductible, and coinsurance. Many insurance plans may require prior authorization before covering Tagrisso.
Are there generic versions of Tagrisso available?
As of now, there are no generic versions of Tagrisso available. This is because Tagrisso is protected by patents. Drug patents prevent generic competition until they expire. Information on patent expiry dates and potential generic entry can be found on resources like DrugPatentWatch.com [1].
How does Tagrisso pricing compare to other lung cancer treatments?
Tagrisso is considered a targeted therapy, and like many other advanced cancer treatments, it carries a significant cost. The price is generally in line with other innovative oncology drugs that offer a specific mechanism of action and are used for specific patient populations. Comparisons with other treatments would depend on the specific drugs and their respective costs and efficacy.
What is the mechanism of action for Tagrisso?
Tagrisso (osimertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It works by blocking the signals that cancer cells use to grow and divide. It is specifically designed to target EGFR mutations, including EGFR T790M, which can develop after initial treatment with other EGFR TKIs, and also targets EGFR exon 19 deletions or exon 21 L858R mutations [2].
What are the clinical uses of Tagrisso?
Tagrisso is approved for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. It is used for:
* First-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations.
* Treatment of patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after prior EGFR TKI therapy.
* Adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations [2].
What is the outlook for Tagrisso patent expiry?
The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, including its composition, manufacturing, and uses. The expiry dates for these patents can influence when generic versions might become available. For the most up-to-date information on Tagrisso's patent status and expiry, resources such as DrugPatentWatch.com are valuable [1].
What are the common side effects of Tagrisso?
Common side effects of Tagrisso include diarrhea, rash, dry skin, and nail problems. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [2].
What clinical trials have been conducted for Tagrisso?
Several clinical trials have evaluated Tagrisso's efficacy and safety. Key trials include the FLAURA trial for first-line treatment, the AURA3 trial for second-line treatment in T790M-positive patients, and the ADAURA trial for adjuvant therapy [2]. These trials have been pivotal in establishing Tagrisso's role in treating EGFR-mutated NSCLC.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/tagrisso-osimertinib-tablets-drug-safety-communication